Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
RNA Editing Pionee | Korro Bio leads in RNA editing therapies, with KRRO-110 for Alpha-1 Antitrypsin Deficiency advancing to Phase 1/2 trials, promising a potential breakthrough in genetic disorder treatment |
Market Opportunity | Explore the vast potential in AATD treatment, with 200,000 patients in the US and EU, and Korro Bio's strategic positioning to capture a significant market share |
Financial Health | Delve into Korro Bio's solid financial footing, with a cash runway extending to 2026 and a healthy current ratio of 8.79x, supporting crucial R&D efforts |
Analyst Optimism | Discover why analysts set price targets ranging from $105 to $120, reflecting confidence in Korro Bio's innovative platform and potential for multi-indication applications |
Metrics to compare | KRRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKRROPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.7x | −1.4x | −0.5x | |
PEG Ratio | −0.03 | −0.03 | 0.00 | |
Price/Book | 1.1x | 1.6x | 2.6x | |
Price / LTM Sales | 30.6x | 10.0x | 3.3x | |
Upside (Analyst Target) | - | 309.8% | 43.5% | |
Fair Value Upside | Unlock | 32.8% | 6.9% | Unlock |